TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in Rrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: malalignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correlation of PEth with self-reported alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of imatinib
Endpoint domain: Adverse events/effects
Primary endpoint: Mean MRSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring analgesics within 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to first analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in total daily servings of fruits and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of implementation of physical activity breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vitamin D status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-10+ regulatory CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Residual neuromuscular blockade (TOF ratio < or = 0.9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Arterial oxygen saturation < 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence, severity, and duration of hypoxemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Development of confirmed clinical neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Healing at day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HAM-A scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in HAM-D scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported sociability
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Diaphragmatic paresis after block
Endpoint domain: Adverse events/effects
Primary endpoint: Weight for age Z-score (WAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adjusted relative risk for tuberculosis
Endpoint domain: Mortality/survival
Primary endpoint: Life satisfaction scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: perinatal mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: premature livebirth rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: plasma proANP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vasopressor treatment required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean level of impairment caused by the hernia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative pain at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of wound events
Endpoint domain: Adverse events/effects
Primary endpoint: sodium MRI PDS increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proton T(2) PDS increase of gastrocnemius muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery of normal performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time to baseline subjective sleepiness levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remoralization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: symptoms of panic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of GDM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal weight loss in the first year post-partum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sit-to-stand performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain measures
Endpoint domain: Adverse events/effects
Primary endpoint: Signs of infection or surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: lumbar flexion range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent calories from fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: consumption of fruits and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalized TSH prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TSH increase >10 mU/l prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: early continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical signs of lipoatrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total limb fat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid profile changes (triglycerides, HDLc, apolipoprotein A1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: bone pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative drainage amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate airway support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ucOC concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of visceral pain
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of nausea and/or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Pain (visual analog scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vibro-tactile threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA <2000 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined HBeAg seroconversion with HBV DNA <2000 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sCD40 ligand level in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vo(2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of side effects (itching, nausea/vomiting)
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity of DNA image cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total contrast dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intervention intentions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: legal knowledge of sexual assault
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Theophylline Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theophylline AUC0‐tlqc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of radioactive cell cholesterol removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median cumulative numbers of newly active lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Segmental colonic transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oswestry pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Epworth Sleepiness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of increase in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of target body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of decrease in obsessive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy for adhering to low-fat diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of moderate exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean aggregate symptom scores (AUC in 15 minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fundic relaxation (balloon volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Implementation success
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visual analogue scale pain values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OHIP‐49 score for handicap
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: amount of glucose excreted in the urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma glucose parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood of attendance at Health Checks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to achieve hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of early radial artery occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: Performance in 2000-m rowing events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroop Word-Color task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of satisfaction with the amount of feedback received
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: positive learning experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of CD3(+) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blastogenic response to phytohemagglutinin and anti‐CD3 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of cohesive and mixed failures
Endpoint domain: Adverse events/effects
Primary endpoint: Cases of respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: delirium diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Breast milk TGF-β2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of diarrhea in infants
Endpoint domain: Adverse events/effects
Primary endpoint: Intentions to engage in lifestyle change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma HIV-1 RNA < 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Median CD4+ cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 5-HTT binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitreous echodensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF degradation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEI‐VFQ‐39 results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of unclogged TTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excess ICD off time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of caregiver handoffs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: morphine consumption reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perception of self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PSA recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: More awakenings (arousals >/=60 seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quiet sleep duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of deoxycholic acid in the fasting state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: faecal levels of chenodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: faecal levels of cholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: faecal levels of ursodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median reductions in inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: rosiglitazone plasma AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rosiglitazone half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apparent oral bioavailability of topotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral corticosteroid use for asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral care knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: oral care behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischaemic heart disease
Endpoint domain: Mortality/survival
Primary endpoint: ARR (Annualized Relapse Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: L2-4 aBMD z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Volumetric L2-4 BMD (vBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: ECT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutropenia G3‐‐4
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative nausea and vomiting (PONV) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional antiemetic and analgesic need
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 6-year disease-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 24-h urine phosphorus excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-h urine fractional excretion of phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart Rate Variability (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma DHA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma EPA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of DHA and EPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjacent enamel demineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of patent foramen ovale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intensity of left ventricular opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of precordial echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abnormal FHR detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from detection of abnormal FHR to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional impairment at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Moderate or severe LBP at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in anxiety as a trait
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CONSORT score
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Coleman Methodology Score
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fibromuscular hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood alcohol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pure-tone thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pitch pattern sequence test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: dichotic digit test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of youth who reported ever having engaged in vaginal intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of conversion from positive to negative cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of skin rash as an adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: therapeutic failures due to sedative inefficacy
Endpoint domain: Adverse events/effects
Primary endpoint: Aggression criteria met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of specialty treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: learning retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: current U-Hg excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative U-Hg excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End of V˙O2max test power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of remaining without additional analgesic intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first appearance in plasma (Tlag)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NOx serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving HbA1c <= 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean FPG decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean mass preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective antibody titers to hepatitis B, diphtheria and tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of acute respiratory infections rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of main disease exacerbations in patients with COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term control of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remineralisation of enamel subsurface lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reasons for living
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of low birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Inotrope scores in the ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ICU time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes